Articles tagged with Glioblastomas
Researchers at Houston Methodist used a helmet generating a noninvasive oscillating magnetic field to treat end-stage recurrent glioblastoma. The treatment resulted in a 31% reduction of the tumor mass, with significant shrinkage appearing to correlate with the treatment dose.
Researchers discovered that glioblastoma (GBM) causes epigenetic changes in CD4 T-cells, affecting their function and differentiation. The study found significant inter-patient variability in these changes, which could help select patients for immunotherapy.
Researchers discovered that laminins, specifically laminin γ1, play a crucial role in mediating cell attachment and penetration for oncolytic viruses like H-1PV. This finding may lead to the development of more efficient clinical trials with reduced costs and approval times.
A new study reveals similarities between glioblastoma and melanoma, as well as unique immunosuppressive factors specific to glioblastoma microenvironment. This framework can be used to uncover pathophysiological and molecular features that determine the effectiveness of immunotherapies.
Researchers discovered hematopoietic stem cells in glioblastomas, which promote division of cancer cells and suppress the immune response. These blood stem cells stimulate tumor growth and produce immunosuppressive messengers.
Researchers engineered NK cells to resist immune suppression and eliminated glioblastoma stem cells using inhibitors targeting TGF-β receptors. The study suggests a combinatorial approach of NK cell-based immunotherapy with disruption of the TGF-β signaling axis for treating glioblastoma.
The company's 3D Predict assay has been validated for predicting responses to temozolomide in glioblastoma patients, with predictive accuracy comparable to its previous results in ovarian cancer. The test identifies future responders and non-responders, enabling personalized treatment strategies.
A British man diagnosed with IDH1-mutant glioblastoma has lived with a growing tumor for over 80 months on a ketogenic diet. Researchers believe this reflects the benefits of using the body's own metabolism to fight cancer, offering a non-toxic alternative to chemotherapy and radiation therapy.
Researchers identify a new class of mibefradil-based DNA repair inhibitors, which could be further advanced into pre-clinical testing and eventually clinical trials for glioblastoma radiosensitization. The compounds retain potency as DNA repair inhibitors while demonstrating reduced hERG and CYP450 enzyme inhibition.
Researchers discovered MCAD's protective role in glioblastoma cells, which relies on the enzyme to detoxify toxic byproducts of fatty acid metabolism. Inhibiting MCAD appears to be specific and potent in killing glioblastoma cells.
Researchers at Massachusetts General Hospital have developed a strategy to reprogram regulatory T cells in the brain to attack glioblastoma tumors. By targeting a specific receptor on these cells, they can convert them into tumor-fighting immune cells, offering a possible solution to overcome resistance to immunotherapy.
A team of researchers from Virginia Tech and City of Hope aim to improve CAR-T cell therapy for glioblastoma multiforme by studying the impact of fluid flow on the treatment's success. They believe they can use fluid flow to encourage T cells to move deeper into tumors and kill invading cancer cells.
Researchers found that piperlongumine binds to and inhibits TRPV2 protein, which is overexpressed in glioblastoma, a type of brain cancer. The treatment radically shrank tumors and extended life in two mouse models.
Researchers at the University of Minnesota identified a new drug target for glioblastoma patients who defy conventional wisdom by surviving beyond expectations. Glioblastoma cells subvert immune system cells called microglia and macrophages, leading to tumor growth.
A new biomedical implant, microMESH, has been developed to treat glioblastoma multiforme. The device wraps around tumor masses, delivering drugs in a controlled, prolonged manner, increasing therapeutic efficacy.
Researchers propose a novel therapeutic strategy combining temozolomide with dianhydrogalactitol to overcome resistance mechanisms in glioblastoma. The combination shows synergistic effects in slowing tumour growth, suggesting a promising new approach for treating aggressive brain tumors.
A new study has found that inhibiting a protein called SELP can block the spread of Glioblastoma cancer cells in the brain. By doing so, the treatment may be able to slow down or even halt the progression of this deadly type of brain cancer.
Researchers at WashU Medicine found that administering chemotherapy drug temozolomide in the morning improved overall survival by about 4 months compared to evening, with an average increase of 3.5 months in patients with MGMT methylated tumors. The study suggests that adjusting timing of standard treatment could enhance effectiveness.
Researchers at VCU Massey Cancer Center have identified a crucial link between the development and growth of glioblastoma multiforme, the most aggressive type of brain cancer. The gene YTHDF2 drives increased cholesterol levels in GBM cells, paving the way for potential new treatments targeting this gene.
A new study mapped glioblastoma in genetic and molecular detail, revealing four distinct immune subtypes and potential targets for therapy. The research identified key signaling hubs, gene expression patterns and protein modifications that drive tumor growth.
Researchers at UCLA Jonsson Comprehensive Cancer Center identified a new approach combining an anti-psychotic drug, a statin and radiation to improve overall survival in mice with glioblastoma. The triple combination extended median survival 4-fold compared to radiation alone, providing hope for improved treatment options.
Researchers developed a new method to classify brain tumors using RNA analysis, achieving high accuracy rates compared to traditional methods. The study found that this approach can identify patients with a worse prognosis and detect secondary glioblastomas not detected by other methods.
Researchers at McGill University identified a new cellular pathway controlling cell surface receptor proteins that limits brain tumor growth and spread. Restoring the activity of Rab35, a protein involved in this pathway, may be a new therapeutic strategy for glioblastoma.
Researchers found that brain tumour growth may be triggered by mutations in cells generated to replace damaged tissue after an injury. The study provides new insights into how glioblastoma develops and could lead to targeted therapies.
Researchers have developed molecular reporters that reveal how immune cells strengthen brain tumors, making them more aggressive. The technology has the potential to guide therapy development and is applicable to various biological systems.
The Luxembourg Institute of Health (LIH) research team discovered a key regulator, ZFAND3, that drives glioblastoma invasion by activating specific genes. Deactivating or overexpressing ZFAND3 in GBM cells impaired or enhanced their invasive capabilities, respectively.
Research found that neutrophils, a type of white blood cell, cause tissue death in brain cancer tissues, leading to poor survival rates for glioblastoma patients. The study identified ferroptosis as the underlying mechanism, which promotes tumor growth.
Researchers found that concurrent dexamethasone administration with an immune checkpoint inhibitor reduced survival in both immunosensitive and immunoresistant mouse models. In human patients, those taking dexamethasone at baseline had significantly worse overall survival compared to non-users.
Researchers have created a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma, showing improved survival rates in mice. The developed nanomicelle accurately senses the pH lowering in tumor tissue and releases the contained anticancer drug.
A phase II trial found no statistically significant overall survival differences between dose-intensification radiation therapy (IMRT) and standard-dose radiation therapy with temozolomide treatments. However, MGMT methylation and RPA were predictive of progression-free survival.
A newly developed prodrug has been shown to selectively target and destroy glioblastoma cells, improving outcomes when combined with standard therapies. In a mouse model study, the drug extended survival by more than a factor of three and was curative in nature.
Glioblastoma multiforme is the most aggressive brain cancer with low five-year survival rate due to rapid development of radioresistance. Researchers from Hokkaido University and Stanford University identified Rab27b and epiregulin as key molecules contributing to radioresistance.
A $10.4 million NIH grant will explore the molecular level differences in glioblastoma incidence, survival, and treatments between males and females. Researchers aim to gain a better understanding of sex differences in tumor growth, diagnosis, and treatment for more personalized therapies.
Glioblastoma patients with mutated Wnt signaling exhibit increased PD-L1 production and reduced T cell infiltration. Targeting the Wnt pathway could improve immunotherapy's efficacy in treating various cancers.
A McGill-led study reveals that suppressing the OSMR gene can improve radiation therapy effectiveness and expand lifespan in preclinical mouse models. Glioblastoma's resistance to therapy is overcome by starving cancer stem cells with energy production halted.
Researchers developed a nanomedicine-based strategy for chemo-immunotherapy that eradicated PTEN-negative glioblastoma cells. The combination of epirubicin-encapsulating nano-micelles and immune checkpoint inhibitors increased tumor-infiltrating T cells and reduced immunosuppressive cells, effectively killing cancer cells.
Researchers found that targeting purine metabolism can disrupt DNA repair and increase sensitivity to radiation, offering a new approach to overcome resistance. A clinical trial is planned to test the effectiveness of an FDA-approved drug in human patients.
Researchers at the Wellcome Sanger Institute have engineered a new mouse model to study glioblastoma, the most aggressive type of brain cancer. The study identified over 200 genes that contribute to the development and growth of glioblastoma, providing potential new drug targets.
A new study published in Nature Communications suggests that glioblastoma tumors may originate from a pool of stem cells located in the subventricular zone (SVZ) of the brain, which is distinct from where the tumor becomes lethal. This finding offers potential new options for treating this aggressive brain cancer.
Researchers have identified AVIL as an oncogene that plays a critical role in the development of glioblastoma. Targeting this gene shows promise as an effective approach for treating the disease.
Researchers at Ohio State University found that blocking an enzyme used by glioblastoma cells to store fats may be a new way to treat the deadly disease. This approach could also apply to other types of cancers that use lipid droplets for energy.
A new PET radiotracer has been proven safe and effective in imaging malignant brain tumors with high sensitivity. The radiotracer targets αvβ3 integrin, which is overexpressed in glioblastomas, allowing for superior visualization of tumors.
Researchers have developed a novel immunotherapy using genetically modified natural killer cells to target and kill cancer cells in glioblastoma multiforme, a highly aggressive brain tumor. The treatment approach has shown high efficiency and is considered safer than other cell-based therapies.
Researchers developed a promising immunotherapy treatment for glioblastoma using CD133-targetting CAR-T therapy, which showed enhanced activity in preclinical models of human glioblastoma. The therapy was considered successful due to reduced tumor burden and improved survival rates.
Researchers discovered that lumefantrine, an FDA-approved anti-malarial drug, can inhibit the genetic element Fli-1 controlling resistance to radiation and chemotherapy in glioblastoma multiforme. Lumefantrine also suppresses tumor cell growth and inhibits key processes regulating cancer invasion and spread.
A new predictor for brain cancer patients' life expectancy has been developed using a genome-wide pattern of DNA copy numbers. The pattern identifies patients who survive for a median of three years, three times longer than those without it.
A new platform has been developed to deliver molecules that target specific genes within cells, showing promise in treating glioblastoma brain cancer. The system uses a modified form of diphtheria toxin to escape the cell's endosome and deliver therapeutic vehicles.
A combination of immunotherapy agents encourages immune cells to consume tumors and alert others to attack, boosting survival for glioblastoma patients. The therapy, tested in a mouse model, successfully shrank tumors and extended life, with 55% of animals surviving over the course of the study.
Researchers discovered that PHIP protein resides at the leading edge of GBM cells, enabling other adhesion proteins to deepen the grip of cancerous cells on healthy brain tissue. Suppressing PHIP helped inactivate proteins that form the machinery for tumor cell movement, driving aggressive behavior.
Researchers developed a new CAR T cell therapy using chlorotoxin, a component of scorpion venom, to target glioblastoma cells. The therapy showed promise in killing tumor cells while ignoring healthy tissue.
A new Penn study found that imaging techniques, such as MRI, may help identify which glioblastoma patients are best candidates for liquid biopsies. The research showed a correlation between the blood-brain barrier and macrophage density with circulating DNA levels, suggesting the potential for personalized treatment decisions.
New research from Penn Medicine suggests blocking the Wnt pathway can make chemotherapy more effective against glioblastoma. The study found that targeting stromal cells, which act like stem cells and promote tumor growth, may be an effective way to overcome treatment resistance.
A retrospective study found that patients who underwent regular surveillance imaging after surgery had similar median survival rates to those who only returned when they felt symptoms of recurrence. The results suggest less frequent imaging could improve patient convenience and reduce costs.
A retrospective study by researchers at UC San Francisco found that removing the non-contrast-enhancing tumor increases survival for adults with glioblastoma. Patients with IDH-mutant tumors who underwent resections of both contrast-enhancing and non-contrast-enhancing tumor had a significantly longer average survival time, around 37.3...
The Akay Lab has developed a new microfluidic brain cancer chip that can simultaneously administer multiple drugs and assess their response to glioblastoma cells. The device enables fast drug combination testing in as little as two weeks, potentially improving patient survival rates.
UC San Diego researchers identified αvβ5 integrin as the key contributor to Zika virus' ability to infect brain cells. Blocking this integrin with antibodies or small molecule inhibitors effectively prevents Zika virus from infecting both normal brain stem cells and cancer stem cells.
A new study found that reinforcing the meningeal lymphatic network increases tumor antigen traffic from the meninges to lymph nodes, triggering activation of immune cells against the tumor. This approach combines with existing immunotherapy for effective glioblastoma eradication.
Scientists have found a novel method to combat glioblastoma, a deadly brain tumor, by introducing VEGF-C into the cerebrospinal fluid of mice. This approach significantly extended survival rates when combined with immune system checkpoint inhibitors, offering new hope for treatment options.
Researchers at Mount Sinai are exploring new treatments for brain tumors, including magnetic hyperthermia therapy and studies on glioma dormancy and tumor microenvironment. The grant funding will support five-year projects focused on improving patient outcomes through innovative therapies.
Researchers have developed glioblastoma organoids from patient tissue, allowing them to rapidly test personalized treatment strategies. The models retain features from the primary tumor and can be used to explore ways to attack it.